Skip to main content
. 2016 Jun 16;1(9):e87607. doi: 10.1172/jci.insight.87607

Figure 4. PRL3-zumab is more effective as a monotherapy rather than when coadministered with 5-fluorouracil or 5-fluorouracil alone.

Figure 4

Four treatment groups were used to treat PRL-3+ SNU-484 orthotopic tumors: placebo (group 1), PRL3-zumab monotherapy (group 2), PRL3-zumab and 5-fluorouracil (5-FU) combination therapy (group 3), or 5-FU alone (group 4). (A) Excised stomachs from each group of mice at day 28, with orthotopic tumor areas framed with black lines, and mean gastric tumor volumes in each group at day 28. Scale bar: 10 mm. n = 5 per group; P < 0.001, 1-way ANOVA; data represent mean ± SEM. (B) Representative images of Giemsa-stained blood smears from each group before the start of therapy (day 0) and at the end of the experiment (day 28) and mean wbc count from blood smears from each mouse at day 28. wbc are stained blue. Scale bar: 40 μm. n = 5 per group; P < 0.001, 1-way ANOVA; data represent mean ± SEM.